Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Carfilzomib + Dexamethasone + Linvoseltamab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carfilzomib | Kyprolis | PR-171 | Kyprolis (carfilzomib) binds to the 20S proteasome and inhibits its protein degradation activity, thereby leading to the accumulation of ubiquinated proteins, which may result in apoptosis and growth arrest in tumor cells (PMID: 26893241). Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone, or in combination with Darzalex Faspro (Daratumumab and hyaluronidase-fihj) and dexamethasone is FDA-approved for use in patients with multiple myeloma (FDA.gov). | |
Dexamethasone | Adexone | Desametasone | ||
Linvoseltamab | REGN5458|REGN-5458|REGN 5458|Anti-BCMA/CD3 BiTE | CD3 Antibody 97 TNFRSF17 Antibody 19 | Linvoseltamab (REGN5458) is a bispecific antibody that binds to TNFRSF17 (BCMA) and CD3 with potential antitumor activity (Blood (2019) 134 (Supplement_1): 3176). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05137054 | Phase I | Bortezomib + Dexamethasone + Linvoseltamab Carfilzomib + Dexamethasone + Linvoseltamab Dexamethasone + Lenalidomide + Linvoseltamab Daratumumab + Dexamethasone + Linvoseltamab | REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | USA | FRA | ESP | 1 |